1. 1)C.F.Ladik,G.P.Stoehr,M.A.Maurer,Precautionary measures in the preparation of antineoplastics,Am.J.Hosp.Pharm .,37,1184-1186 (1980).
2. 2)S.Venitt,C.C.Sleigh,J.Hunt,V.Speechley,K.Brlggs,Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs : urinary mutation assays and urinary platinum as markers of absorption,The Lancet ,14,74-76 (1984).
3. 3)I.Stucker,A.Hirsch,T.Doloy,I.B.Sigeac,D.Hemon,Urine mutagenicity,Chromosomal abnormalities and Sister chromatid exchange in lymphocytes of nurses handling cytostatic drugs,Int.Arch.Occup.Environ.Health ,57,195-205 (1986).
4. 4)K.Labuhn,B.Valanis,R.Schoeny,K.Loveday,W.M.Vollmer,Nurses’and pharmacists’exposure to antineoplastic drugs : Findings from industrial hygiene scans and urine mutagenicity tests,Cancer Nursing ,21,79-89 (1998).